Q-omics provides the consensus-scored TLN1 profile across patient tissues and cancer cell-line models. TLN1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TLN1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TLN1 protein abundance shows 37,347 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where TLN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLN1 survival associations across molecular data types. TLN1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLN1 RNA expression–survival associations across cancer types. High TLN1 expression shows unfavorable associations in ACC, CESC, LGG, KICH and BLCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TLN1 RNA expression.
This table summarizes TLN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TLN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLN1 shows lower tumor expression in BLCA, LUAD, UCEC and LUSC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher TLN1 RNA expression in tumor versus normal tissue (log2 FC = +0.966, t-test p < 0.001).
This table shows molecular features associated with TLN1 in patient tissues and cancer cell lines. In patient samples, TLN1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TLN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
